US Organ-on-Chip Market (2024-2029)
The US Organ-on-Chip Market was valued at $27.92 Million in 2024 and projected to reach to $147.16 Million by 2029, representing a compound annual growth rate of 39.4%. The US organ-on-chip market is poised for transformative growth through 2029, driven by technological advancements and increasing pharmaceutical industry adoption.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Organ-on-Chip Market Trends and Insights
- This exceptional growth trajectory reflects the US healthcare sector's increasing adoption of microphysiological systems for drug testing, disease modeling, and personalized medicine applications.
- The US market benefits from strong R&D investment, advanced biotechnology infrastructure, and regulatory support for innovative in vitro technologies that reduce reliance on animal testing. Driving this expansion, the US is leveraging organ-on-chip platforms to accelerate pharmaceutical development cycles and improve clinical trial outcomes.
- The US pharmaceutical and biotech industries are integrating these technologies to enhance drug efficacy prediction and toxicity screening.
- By 2029, the US market is expected to solidify its position as a global leader in organ-on-chip commercialization, supported by venture capital funding, academic partnerships, and FDA recognition of these platforms as viable alternatives to traditional testing methods..
Key Market Statistics
- CAGR (2024-2029) 39.4% CAGR
- Market Size, 2024 ~USD 27.92 Million
- Forecast, 2029 ~USD 147.16 Million
- Country US
US Organ-on-Chip Market Overview
Rapid US Market Expansion :
The US organ-on-chip market is projected to grow from $27.92 million in 2024 to $147.16 million by 2029, representing a robust 39.4% CAGR. This exceptional growth outpaces the global average of 38.6%, positioning the US as a leading market for microphysiological systems innovation.
Strong R&D Investment Ecosystem :
The US healthcare sector's substantial investment in research and development drives adoption of organ-on-chip technologies. Leading academic institutions, biotech companies, and pharmaceutical firms are actively integrating these systems into their drug discovery and development pipelines.
Drug Testing & Regulatory Advancement :
US regulatory bodies increasingly recognize organ-on-chip systems as viable alternatives to traditional animal testing models. This regulatory acceptance accelerates adoption among pharmaceutical companies seeking to streamline drug development timelines and reduce costs.
Personalized Medicine Applications :
US healthcare providers are leveraging organ-on-chip technology for personalized medicine and disease modeling. These systems enable patient-specific drug response testing and precision treatment planning, aligning with the growing demand for individualized healthcare solutions.
US Organ-on-Chip Market Dynamics
- Major US biotech and pharmaceutical companies are investing heavily in microphysiological systems to accelerate drug development cycles and reduce preclinical testing costs.
- Regulatory support from the FDA and NIH further validates these technologies as credible alternatives to traditional testing methods. Looking ahead, the US market will benefit from expanding applications beyond drug testing into disease modeling, toxicology assessment, and personalized medicine.
- Collaborations between academic institutions, government agencies, and private sector players will continue to fuel innovation.
- The convergence of organ-on-chip technology with artificial intelligence and automation is expected to unlock new market opportunities and drive sustained double-digit growth through the forecast period..
Related Ecosystem
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- SANOFI
- Merck KGaA
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- The US organ-on-chip market is projected to grow from $27.92M (2024) to $147.16M (2029) at a 39.4% CAGR.
- The US pharmaceutical and biotech sectors are primary drivers, utilizing organ-on-chip technology for accelerated drug development and toxicity screening.
- The US regulatory environment, including FDA support, is enabling faster commercialization and adoption of microphysiological systems.
- The US market leadership is reinforced by substantial venture capital investment, academic research partnerships, and infrastructure supporting innovation in precision medicine.
Organ-on-Chip Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DISEASE-BASED MODELS (Model Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 38.6% from 2024 to 2029 |
| Largest Segment | ORGAN-BASED MODELS (Model Type) |
| Market Size Base Year (Billions) | ~USD 0.12 (2024) |
| Revenue Forecast (Billions) | ~USD 0.63 (2029) |
| Segments Covered | Organ Type, Model Type, Product & Service, Type, Application, Purpose, End User |
US Organ-on-Chip Market Report Segmentation
7 segment dimensions are covered across the global market.
By Organ Type
- Heart
- Intestine
- Kidney
- Liver
- Lung
- Other Organs
By Model Type
- Disease-Based Models
- Organ-Based Models
By Product & Service
- Products
- Services
By Type
- Consumables & Accessories
- Custom Services
- Instruments
- Software
- Standard Services
By Application
- Drug Discovery
- Physiological Model Development
- Stem Cell Research
- Tissue Regeneration & Regenerative Medicine
- Toxicology Research
By Purpose
- Research
- Therapeutics
By End User
- Academic & Research Institutes
- Cosmetics Industry
- Other End Users
- Pharmaceutical & Biotechnology Companies
Target Audience
- Pharmaceutical & Biotech Companies : US-based drug developers need market intelligence to evaluate organ-on-chip adoption for preclinical testing, accelerate time-to-market, and optimize R&D budgets. This data supports technology investment and partnership decisions.
- Medical Device & Instrumentation Manufacturers : Equipment and platform providers require US market sizing and growth forecasts to develop product roadmaps, identify distribution channels, and capitalize on the expanding demand for microphysiological systems infrastructure.
- Venture Capital & Private Equity Investors : US-focused investors need comprehensive market analysis to identify high-potential organ-on-chip startups, assess market timing, and evaluate exit opportunities within the rapidly growing American healthcare technology sector.
- Academic & Research Institutions : US universities and research centers require market data to justify funding proposals, identify collaboration opportunities with industry, and position their organ-on-chip research within the broader US innovation ecosystem.
- Healthcare Policy & Regulatory Bodies : US regulatory agencies and policy makers need market intelligence to understand adoption trends, assess technology impact on drug development timelines, and develop evidence-based guidelines for organ-on-chip validation and approval.
Reasons to Buy this Report
- Market Size & Growth Validation : Gain precise US market valuation ($27.92M in 2024) and verified forecast data ($147.16M by 2029) to support strategic planning, investment decisions, and competitive positioning in the rapidly expanding organ-on-chip sector.
- Competitive Landscape Intelligence : Understand the US competitive dynamics, key players, and market consolidation trends specific to the American organ-on-chip ecosystem. Identify partnership opportunities and acquisition targets within the US market.
- Regulatory & Adoption Insights : Access detailed analysis of FDA regulatory pathways, NIH funding trends, and institutional adoption patterns across US pharmaceutical companies, biotech firms, and research organizations driving market growth.
- Application-Specific Demand Analysis : Explore segmented demand for organ-on-chip applications in US drug testing, disease modeling, and personalized medicine. Identify high-growth application areas and emerging use cases within the American healthcare market.
- Investment & Funding Opportunities : Discover venture capital trends, government funding initiatives, and strategic investment patterns in the US organ-on-chip market. Identify emerging companies and technology platforms attracting US investor interest.
Frequently asked questions
What is the current size of the US organ-on-chip market?
The US organ-on-chip market was valued at $27.92 million in 2024 and is expected to grow to $147.16 million by 2029.
What is the growth rate of the US organ-on-chip market?
The US organ-on-chip market is growing at a compound annual growth rate (CAGR) of 39.4% from 2024 to 2029.
Which industries are driving the US organ-on-chip market?
The US pharmaceutical, biotechnology, and contract research organization (CRO) sectors are primary drivers, utilizing organ-on-chip platforms for drug development, toxicity testing, and disease modeling.
How is the US regulatory environment supporting organ-on-chip adoption?
The US FDA has recognized organ-on-chip technologies as viable alternatives to animal testing, providing regulatory pathways that accelerate commercialization and market adoption.
What factors are contributing to the rapid growth of the US market?
Key factors include increased R&D investment, venture capital funding, academic partnerships, demand for alternatives to animal testing, and the need for improved drug efficacy prediction in the US healthcare system.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the historic, current and forecasted size of the organ-on-chip market. Exhaustive secondary research was carried out to collect information on the market, and its peer markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down approach was employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
The secondary sources referred to for this research study include publications from public sources, such as the National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), ScienceDirect, European Medicines Agency (EMA), company websites among others. Secondary sources also include business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global organ-on-chip market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down approach was used to estimate and validate the total size of the organ-on-chip market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary and primary research
- The revenues generated from the organ-on-chip business of leading players have been determined through primary research and paid secondary sources
- All percentage shares, splits, and breakdowns have been determined using internal analysis of product and service offerings, secondary sources, and verified from industry experts
Global Organ-on-chip Market Size: Top Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Organ-on-a-chip is a system that has natural miniature tissues grown inside microfluidic chips. It is a 3D microfluidic cell culture platform which mimics the mechanics, functions, and physiological responses of a respective organ. This platform is created with microfabrication techniques which creates hollow microchannel lined by living cells and tissues cultured within an organ-relevant physical context, which are continuously perfused with life-sustaining culture medium. According to the US FDA, the organ-chips are designed to accurately recreate the natural physiology and mechanical forces that cells experience in the human body. According to Wyss Institute, organ-on-chips are 3D micro fluidic devices that mimic the structure and functions of living human organs. This technology allows researchers to study the functioning of the organ and the effect of drugs on the organs without using animal models.
Key Stakeholders
- Pharmaceutical companies
- Biotechnology companies
- Research institutions & academic centers
- Regulatory agencies
- Private & government-funding organizations
Report Objectives
- To define, describe, and forecast the global organ-on-chip market by model type, organ type, by product and service, by application, by purpose, by end-user and region
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall organ-on-chip market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
- To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically analyze the market structure and profile the key players of the global organ-on-chip market and comprehensively analyze their core competencies2
- To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the organ-on-chip market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- Twenty five company profiles
Get the Full Organ-on-Chip Market Report
Full forecast, segment splits, and company analysis for all Organ-on-Chip Market.
- Canada Organ-on-Chip Market
- Germany Organ-on-Chip Market
- UK Organ-on-Chip Market
- France Organ-on-Chip Market
- Italy Organ-on-Chip Market
- Spain Organ-on-Chip Market
- China Organ-on-Chip Market
- Japan Organ-on-Chip Market
- India Organ-on-Chip Market
- Australia Organ-on-Chip Market
- South Korea Organ-on-Chip Market
- Brazil Organ-on-Chip Market
- Mexico Organ-on-Chip Market
- Rest Of Europe Organ-on-Chip Market
- Rest Of Asia Pacific Organ-on-Chip Market
- Rest Of Latin America Organ-on-Chip Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
